The NHS's spending watchdog acted unlawfully when it decided to restrict access to drugs that could help thousands of older women with the bone-thinning disease osteoporosis, the high court ruled today. A judge ruled that the National Institute for Health and Clinical Excellence (Nice) wrongly failed to disclose the economic reasoning behind a decision in October to restrict the supply of strontium ranelate, a drug manufactured by Servier laboratories under the brand name Protelos.